Active surveillance is evolving as a management strategy for favorable-risk prostate cancer. Further study is needed to determine the safety of surveillance for specific subgroups of patients, and to clarify the role of genomic markers and image-guided biopsy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
European urology. 2016 Jul 22 [Epub ahead of print]
H Ballentine Carter
The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: .